<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Thor Medical Asa — News on 6ix</title>
    <link>https://6ix.com/company/thor-medical-asa-1</link>
    <description>Latest news and press releases for Thor Medical Asa on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 04 Dec 2025 12:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/thor-medical-asa-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d55366beedb30cb6f7999d.webp</url>
      <title>Thor Medical Asa</title>
      <link>https://6ix.com/company/thor-medical-asa-1</link>
    </image>
    <item>
      <title>RadioMedix and Thor Medical enter supply agreement for thorium-228</title>
      <link>https://6ix.com/company/thor-medical-asa-1/news/radiomedix-and-thor-medical-enter-supply-agreement-for-thorium-228-1</link>
      <guid isPermaLink="true">https://6ix.com/company/thor-medical-asa-1/news/radiomedix-and-thor-medical-enter-supply-agreement-for-thorium-228-1</guid>
      <pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
      <description>OSLO, Norway and HOUSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and RadioMedix, Inc., a U.S. based clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and cancer therapy, have entered into a five-year frame agreement for the supply of thorium-228 (Th-228). The supply of Th-228 will start in 2026, with volumes scaling with incre</description>
    </item>
  </channel>
</rss>